132 related articles for article (PubMed ID: 17725485)
1. Responsiveness of osteoblastic and osteolytic bone metastases to vitamin D analogs.
Peleg S
Crit Rev Eukaryot Gene Expr; 2007; 17(2):149-58. PubMed ID: 17725485
[TBL] [Abstract][Full Text] [Related]
2. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.
Guise TA; Mohammad KS; Clines G; Stebbins EG; Wong DH; Higgins LS; Vessella R; Corey E; Padalecki S; Suva L; Chirgwin JM
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6213s-6216s. PubMed ID: 17062703
[TBL] [Abstract][Full Text] [Related]
3. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
4. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
[TBL] [Abstract][Full Text] [Related]
5. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.
Body JJ
Breast; 2003 Aug; 12 Suppl 2():S37-44. PubMed ID: 14659142
[TBL] [Abstract][Full Text] [Related]
6. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
[TBL] [Abstract][Full Text] [Related]
7. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
8. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.
Larson SR; Zhang X; Dumpit R; Coleman I; Lakely B; Roudier M; Higano CS; True LD; Lange PH; Montgomery B; Corey E; Nelson PS; Vessella RL; Morrissey C
Prostate; 2013 Jun; 73(9):932-40. PubMed ID: 23334979
[TBL] [Abstract][Full Text] [Related]
9. The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.
Özdemir BC; Hensel J; Secondini C; Wetterwald A; Schwaninger R; Fleischmann A; Raffelsberger W; Poch O; Delorenzi M; Temanni R; Mills IG; van der Pluijm G; Thalmann GN; Cecchini MG
PLoS One; 2014; 9(12):e114530. PubMed ID: 25485970
[TBL] [Abstract][Full Text] [Related]
10. Biochemical parameters of bone metabolism in bone metastases of solid tumors (review).
Meijer WG; van der Veer E; Willemse PH
Oncol Rep; 1998; 5(1):5-21. PubMed ID: 9458286
[TBL] [Abstract][Full Text] [Related]
11. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
Keller ET; Brown J
J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
[TBL] [Abstract][Full Text] [Related]
13. Osteolytic and osteoblastic bone metastases: two extremes of the same spectrum?
Ortiz A; Lin SH
Recent Results Cancer Res; 2012; 192():225-33. PubMed ID: 22307378
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D and prostate cancer: biologic interactions and clinical potentials.
Miller GJ
Cancer Metastasis Rev; 1998-1999; 17(4):353-60. PubMed ID: 10453279
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D in Prostate Cancer.
Ahn J; Park S; Zuniga B; Bera A; Song CS; Chatterjee B
Vitam Horm; 2016; 100():321-55. PubMed ID: 26827958
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
[TBL] [Abstract][Full Text] [Related]
17. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
[TBL] [Abstract][Full Text] [Related]
18. C15-functionalized 16-ene-1α,25-dihydroxyvitamin D3 is a new vitamin D analog with unique biological properties.
Kumagai G; Takano M; Shindo K; Sawada D; Saito N; Saito H; Kakuda S; Takagi K; Takimoto-Kamimura M; Takenouchi K; Chen TC; Kittaka A
Anticancer Res; 2012 Jan; 32(1):311-7. PubMed ID: 22213321
[TBL] [Abstract][Full Text] [Related]
19. Role of Wnts in prostate cancer bone metastases.
Hall CL; Kang S; MacDougald OA; Keller ET
J Cell Biochem; 2006 Mar; 97(4):661-72. PubMed ID: 16447163
[TBL] [Abstract][Full Text] [Related]
20. Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
Lamoureux F; Ory B; Battaglia S; Pilet P; Heymann MF; Gouin F; Duteille F; Heymann D; Redini F
Int J Cancer; 2008 Feb; 122(4):751-60. PubMed ID: 17960623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
